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STUDY PROTOCOL Open Access
Reduced nicotine content cigarettes in
smokers of low socioeconomic status: study
protocol for a randomized control trial
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Jennifer Modesto1, Robin Kuprewicz3, Ashley Wilhelm1, Shari Hrabovsky1, Abid Kazi1, Alyse Fazzi2, Jason Liao1,
Junjia Zhu1, Emily Wasserman1, Samantha M. Reilly1, Lisa Reinhart1, Neil Trushin1, Robinn E. Moyer1,
Rebecca Bascom4, Jonathan Foulds1, John P. Richie Jr.1 and Joshua E. Muscat1
Abstract
Background: The Family Smoking Prevention and Tobacco Control Act gave the Food and Drug Administration
jurisdiction over the regulation of all tobacco products, including their nicotine content. Under this act, a major
strategy to reduce harm from cigarette tobacco is lowering the nicotine content without causing unintended
adverse consequences. Initial research on reduced nicotine content (RNC) cigarettes has shown that smokers of
these cigarettes gradually decrease their smoking frequency and biomarkers of exposure. The effectiveness of this
strategy needs to be demonstrated in different populations whose response to RNC cigarettes might be substantially
mediated by personal or environmental factors, such as low socioeconomic status (SES) populations. This study aims to
evaluate the response to a reduced nicotine intervention in low SES smokers, as defined here as those with less than
16 years of education, by switching smokers from high nicotine commercial cigarettes to RNC cigarettes.
Methods/design: Adults (N = 280) who have smoked five cigarettes or more per day for the past year, have not made a
quit attempt in the prior month, are not planning to quit, and have less than 16 years of education are recruited into a
two-arm, double-blinded randomized controlled trial. First, participants smoke their usual brand of cigarettes for 1 week
and SPECTRUM research cigarettes containing a usual amount of nicotine for 2 weeks. During the experimental phase,
participants are randomized to continue smoking SPECTRUM research cigarettes that contain either (1) usual nicotine
content (UNC) (11.6 mg/cigarette) or (2) RNC (11.6 to 0.2 mg/cigarette) over 18 weeks. During the final phase of the
study, all participants are offered the choice to quit smoking with nicotine replacement therapy, continue smoking the
research cigarettes, or return to their usual brand of cigarettes. The primary outcomes of the study include retention
rates and compliance with using only research cigarettes and no use of other nicotine-containing products. Secondary
outcomes are tobacco smoke biomarkers, nicotine dependence measures, smoking topography, stress levels, and
adverse health consequences.
Discussion: Results from this study will provide information on whether low SES smokers can maintain a course of
progressive nicotine reduction without increases in incidence of adverse effects.
Trial registration: ClinicalTrials.gov, NCT01928719. Registered on 21 August 2013.
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Socioeconomic status, Education, Tobacco control
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Background
Reducing the addictiveness of cigarettes by lowering the
nicotine content is a proposed national regulatory policy
[1] that is permissible under the Family Smoking Pre-
vention and Tobacco Control Act (TCA) of 2009 [2].
This act gave the Food and Drug Administration (FDA)
the authority to reduce, but not completely eliminate,
nicotine in tobacco products. This policy could only be
enacted if it benefits public health by lowering harm due
to tobacco exposure. If the levels of nicotine in cigarettes
were reduced to levels that were not addictive, young in-
dividuals who have an interest in smoking might never
develop a dependence on cigarettes, the leading cause of
morbidity and premature mortality in the USA [3]. The
Institute of Medicine and the US Office of the Surgeon
General indicate that a nicotine reduction strategy is
feasible and guidelines need to be developed to imple-
ment this policy [4, 5]. However, potential harms from
this strategy could include (1) the physiological and psy-
chological conditions associated with nicotine with-
drawal and (2) the possibility that smokers may increase
their toxicant inhalation by smoking more in order to
compensate for the reduced nicotine per cigarette (com-
pensatory smoking).
Cigarette smoking is predominantly a health concern
among persons with lower income and less education [6],
referred to herein as persons with a low socioeconomic
status (SES). When considering a national policy, it is ne-
cessary to consider one of the greatest predictors of to-
bacco use, which is low SES [7]. More than one quarter of
adults below the poverty level smoke tobacco, compared
to only 14% at or above the poverty level [8]. Cigarette
smoking is the highest among adults with a graduate edu-
cation degree (GED) certificate (34%) and lowest among
college graduates (3–7%) [8]. Low SES populations not
only have high levels of smoking [7] but also high levels of
other unhealthy behaviors, such as poor eating choices
and lower levels of physical activity [9–12]. This may
present unique challenges to a nicotine reduction strategy.
Disparities in smoking cessation outcomes include
smokers with less education are less likely to intend to
quit, initiate a quit attempt, or be abstinent from smoking
for at least 1 month [13]. The lack of intention to quit and
the inability to quit among low SES smokers contributes
to the clear gradient in smoking prevalence by income
and education. The differences in smoking rates between
low and high SES populations are projected to deviate
even more in the future [14]. Barriers to quitting among
low SES smokers include psychosocial factors (attitude,
social norm, self-efficacy) [15–17], higher stress levels
[18], less social support [19, 20], and an inaccessibility to
treatment [21, 22].
Smoking is a behavior that is reported to relieve stress
[23–26]. However, the stress hormone, cortisol, is shown
to be elevated in smokers compared to non-smokers
[27], and perceived stress levels reduce after smokers
quit [28]. The elevation of cortisol in smokers is attrib-
uted to nicotine exposure [29, 30]. As an additive influ-
ence, cortisol also has been shown to be elevated in low
SES populations, although the findings are not consist-
ent [31]. Elevated levels of stress hormones can have a
deleterious effect on the body [32]. An assessment of
whether the gradual reduction in nicotine changes the
stress hormones in the body is another focus of this study.
Research evaluating reduced nicotine in cigarettes has
been published [33–39]. In an initial study of switching
smokers to research cigarettes with very low nicotine
content [34], participants were asked to smoke their
usual brand of cigarettes and one of five research ciga-
rettes with varying nicotine contents in a progressive
manner (range: 12 to 1 mg/cigarette). At the end of the
study, participants reduced their cigarettes per day, nico-
tine dependence, cravings, and biomarkers of nicotine
[34]. In a 6-month controlled trial of progressively lower
nicotine content cigarettes, 135 current smokers [36]
demonstrated reduced exposure to tobacco constituents
(including nicotine) without increases in cigarette con-
sumption or tobacco smoke byproducts (carbon monox-
ide and polycyclic aromatic hydrocarbons). However, the
mean level of education among the participants was col-
lege graduate (e.g., ~15–16 years of education). An alter-
native strategy from progressively switching from high
to low nicotine cigarettes is a non-progressive switch to
low nicotine cigarettes. In a 6-week study examining the
non-progressive approach, reduced nicotine cigarette
use resulted in reduced nicotine exposure, reduced nico-
tine dependence, and reduced biomarkers [37]. However,
compliance in only using research cigarettes in these tri-
als is a concern [40], and although the extent of non-
compliance was small for many participants, the feasibil-
ity of a nicotine reduction strategy depends on balancing
the need for reducing dependence and the incidence of
tobacco-related disease and minimizing the potential
harms to smokers associated with withdrawal. In a na-
tional nicotine reduction policy, smokers would not have
available their full-strength nicotine cigarettes, and po-
tential harms from this policy include the loss of the
psychological benefits of smoking, a dislike of the taste
of low-nicotine cigarettes, and potential short-term com-
pensation [35, 39, 41–45].
The premise of nicotine reduction is to lower the nicotine
content in cigarettes to non-addicting levels, which could
in theory reduce tobacco addiction in current smokers and
eliminate the onset of dependent cigarette smoking in
young people. Commercial cigarettes typically contain
about 8–9 mg of nicotine per cigarette [46], and the deliv-
ery of nicotine per cigarette to the smoker is around 1 mg,
but it can vary [47]. Based on the bioavailability of nicotine,
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a reduced nicotine content (RNC) of 0.5 mg per cigarette
has been proposed as an addictive cut point [1] and may
make it easier for established smokers to quit [38]. This dif-
fers from smokers switching to “light” cigarettes, a label no
longer allowed under the TCA. Light cigarettes reduce
machine-smoked nicotine and tar yields by various design
changes that increase the ventilation or air flow through
the cigarette such as adding perforations in the filter. The
light cigarettes had similar nicotine content to regular ciga-
rettes, and smokers could cover the ventilation holes to in-
crease their nicotine delivery and circumvent the design
feature [48–51]. In contrast, RNC cigarettes actually con-
tain less nicotine, and compensation is not as feasible, espe-
cially at very low levels of nicotine content. However, some
compensation may still occur if smokers compensate by
smoking more of an individual cigarette or more cigarettes
per day. If high nicotine cigarettes were no longer available
in the marketplace, smokers might compensate by purchas-
ing and consuming high nicotine black market cigarettes
[52]. It could be expected that, without the ability to com-
pensate, smokers would find low nicotine cigarettes un-
acceptable. However, trials of switching to reduced nicotine
research cigarettes have been shown to be successful,
although biomarker data suggest some level of non-
compliance as determined by the ratio of cotinine, the im-
mediate metabolite of nicotine, to the number of research
cigarettes smoked [53]. Significant predictors of non-
compliance were cigarette satisfaction, dependence, and
age. More data are needed to assess the feasibility of this
regulatory policy in high-risk smokers, especially smokers
who have a high degree of dependence, such as low SES
populations. The study described here aims to test the cap-
ability of a nicotine reduction intervention, where low SES
smokers are switched from their usual brand of commercial
cigarettes to progressively lower nicotine content cigarettes
in a randomized controlled trial.
Methods/design
Study population
Cigarette smokers with less than 16 years of education,
with access to the Penn State Milton S. Hershey Medical
Center Hershey, in Hershey, PA or the George Washing-
ton University Milken Institute School of Public Health,
in Washington, DC, who report no quit attempt in the
past month and do not plan to quit smoking in the next
6 months are eligible. Additional eligibility criteria are
outlined in Table 1.
Design
This is a two-arm, double-blind, parallel-group, random-
ized controlled trial. The study consists of four phases
(Baseline I, Baseline II, Randomization, and Treatment
Choice) over 34 weeks (Fig. 1). Participants are random-
ized into either a Usual Nicotine Content (UNC) cigarette
or a Reduced Nicotine Content (RNC) cigarette treatment
group. Table 2 shows the nicotine content dosing schedule
for the two treatment groups. Participants and study staff
are blind to the cigarette treatment group throughout the
trial. Visits occur during the day at the Penn State Univer-
sity College of Medicine Clinical Research Center in
Hershey, PA and George Washington University Milken
School of Public Health and Medical Faculty Associates in
Washington, DC.
Primary Aim
The primary aim of the trial is to determine adherence
to a regimen of progressively lowering cigarette nicotine
levels. Efficacy will be determined by the ability to
complete the study and degree of compliance in the
UNC versus RNC treatment groups. The participant’s
compliance with using only the research cigarettes and
no other nicotine-containing products including their
usual brand of cigarettes will be determined by both
self-report and biochemical measures. We hypothesize
that non-compliance and drop-out rates will be higher
in the RNC versus the UNC treatment group.
Secondary Aims
The secondary aims are as follows:
Table 1 Inclusion and exclusion criteria
Inclusions:
Age 18–65
Education <16 years or < Bachelor’s degree
Cigarette frequency ≥5 cigarettes per day
Cigarette history Continuously for at least the last 12 months
Cigarette flavor Willing to smoke one flavor of cigarette
(menthol or non-menthol)
Comprehension Able to read and write in English and to
understand and consent to
study procedures
Smoking cessation Made no serious quit attempt with/without
pharmacotherapy in the prior 1 month and
have no plans to quit in the next 6 months
Availability Accessibility to study centers and to receive
phone calls for the next 8 months
Exclusions: Current pregnancy or nursing, unstable or
serious medical conditions, prisoners or
subject to correctional supervision, systolic
blood pressure ≥160 mmHg, use of non-
cigarette nicotine delivery product in the
past week, difficulty providing blood samples,
regular use of illegal drugs, inpatient treatment
for substance abuse or mental health condition
in past 6 months, alcohol abuse hindering person’s
ability to participate, other members of the
household currently participating in a trial related
to reduced nicotine cigarettes, major surgery
planned in the next 8 months (not including
outpatient), or any other factor that may affect
adherence or pose a health risk to the participant
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1. Determine the effect of progressive nicotine content
reduction on nicotine metabolites and other
biomarkers of smoking exposure. We hypothesize
that the gradual reduction of nicotine from
progressively lowering nicotine exposure will lead to
lower levels of blood nicotine metabolites and
nicotine-derived carcinogens, while not affecting
overall cigarettes smoked per day
 Determine the modifying effect of menthol on
progressive nicotine content reduction and
biomarkers. We hypothesize that menthol will
not modify the effect of progressive RNC
cigarettes on the above biomarkers
2. Determine if a gradual reduction in nicotine content
in RNC cigarettes is associated with a reduction in
stress. We hypothesize that the reduction in nicotine
will lead to a reduction in levels of psychological
stress and stress biomarkers
3. Determine if smoking topography measures change
in response to RNC versus UNC cigarettes. We
hypothesize that smoking topography measures
(i.e., puff volume, puff count, puff flow, and puff
duration) will increase for smokers in the RNC
cigarette group due to compensatory smoking
Primary outcomes The primary outcomes are the
following:
 Non-compliance (use of other nicotine-containing
products) by biochemical and self-report measures
during the randomization phase
 Participant drop-out rate during the randomization
phase
Secondary outcomes Secondary outcomes (measured
from baseline to the end of the randomization phase) are:
Fig. 1 Study flow diagram
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 Changes in cigarettes per day
 Changes in nicotine (measured by plasma cotinine)
and tobacco smoke exposure (measured by expired
carbon monoxide, tobacco-specific N-nitrosamines)
biomarkers
 Changes in measures of oxidative stress including
glutathione (oxidized:reduced ratio) and 8-isoprostanes
 Changes in nicotine dependence and withdrawal
symptoms
 Changes in stress (in subgroup), measured by the
Perceived Stress Questionnaire and salivary cortisol
and alpha amylase
 Changes in smoking topography measures (in
subgroup), measured by puff volume, puff count,
puff flow, puff duration, inter-puff interval
 Changes in adverse health effects (e.g., high blood
pressure, adverse respiratory symptoms)
 Proportion of participants choosing to make a quit
attempt with biochemically verified abstinence
Research cigarettes
SPECTRUM research cigarettes are available only
through the National Institute of Drug Abuse Drug Sup-
ply Program (NOT-DA-14-004) and are obtained via an
Investigational Tobacco Product (ITP) application. The
physical properties of these cigarettes are described else-
where [54]. An ITP is defined as “a new or modified risk
tobacco product that is not legally marketed; or a to-
bacco product that is required to comply with a tobacco
product standard and that does not conform in all re-
spects to the applicable tobacco product standard and is
intended for investigational use.” An ITP application
requires a detailed protocol submission and plans for ad-
herence to the product usage. SPECTRUM research cig-
arettes in regular and menthol flavors are shipped from
the Research Triangle Institute, Research Triangle Park,
NC, USA. Cartons contain 10 packs of cigarettes, and
each pack contains 20 cigarettes. Each cigarette is ap-
proximately 83 mm long. All cigarette packs are labeled
with a Surgeon General’s Warning and a “for research
purposes only” indication.
Blind coding of the research cigarettes
SPECTRUM cigarette cartons are shipped to the Depart-
ment of Pharmacy at Penn State Milton S. Hershey
Medical Center. Each carton received comes with the
manufacturer’s barcoded labels that identify the nicotine
content and a batch/lot number. Individual packs and
cigarettes do not contain any identifiable labels. The
manufacturer’s labels are recorded and removed from
the carton and replaced with a blind code number by an
unblinded cigarette administrator who has no direct
contact with participants. Each carton is packaged with
a sheet of 10 additional labels of the same blind code
number to be affixed to the individual packs within the
carton. The link between the blind code number and the
nicotine content of each carton is housed in our propri-
etary Cigarette Management System (CMS), which
allows the cigarette administrator to dispense appropri-
ate cartons to participants in a blinded fashion. The
computer-generated randomization sequence is housed
within the CMS and stratified by study site and cigarette
flavor (regular or menthol). Within each of the strata a
block randomization is used. Unblinding of the cigarette
Table 2 Nicotine content dosing schedule
Phase Baseline
Phase I
Baseline Phase II Randomized Double-Blind Phase Treatment
Choice
Phase









































Approximate nicotine content in mg/cigarette (mg/gram)a
RNC cigarette
group
13b (19) 11.6 (16.5) 7.4 (10.6) 3.3 (4.7) 1.4 (1.9) 0.7 (0.9) 0.2 (0.3) Variable
UNC cigarette
group
13b (19) 11.6 (16.5) 11.6 (16.5) 11.6 (16.5) 11.6 (16.5) 11.6 (16.5) 11.6 (16.5) Variable
Abbreviations: RNC reduced nicotine content, UNC usual nicotine content
SPECTRUM Tobacco Product Master File Codes used for RNC group (non-menthol/menthol) are NRC600/NRC601 or NRC602, NRC500/NRC501, NRC400/NRC401,
NRC300/NRC301, NRC200/NRC201, and NRC102/NRC103. SPECTRUM Tobacco Product Master File Codes used for UNC group (non-menthol/menthol) are NRC600/
NRC601 or NRC602
aThese are averages of menthol/non-menthol cigarettes at each level based on estimated 0.7 g tobacco content per cigarette and nicotine concentrations based
on Richter et al. (2016) [54]
bApproximate mean nicotine content and concentration of commercially available cigarettes based on Connolly et al. (2007) [62]
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allocation is only permissible if it becomes medically ne-
cessary for the safety of the participant.
Early withdrawal of participants
This study is designed to identify participants who are not
able or unwilling to comply with the full study protocol by
having two baseline phases (I and II) prior to
randomization. During Baseline Phase I, participants
smoke their usual brand of cigarettes for 1 week. At Base-
line Phase II, all participants smoke SPECTRUM research
cigarettes with normal nicotine content (about 11.6 mg).
During Baseline Phases I and II, participants are with-
drawn if they report smoking other products or using
other nicotine-containing products at more than one visit.
This includes any number of usual brand cigarettes (when
research cigarettes are received), cigars, pipes, snuff, chew,
hookahs, electronic cigarettes, marijuana, or any other il-
legal smoked substance or nicotine-containing product.
During Baseline Phase II, participants are withdrawn if:
1. The total cigarette consumption includes more than
10% of non-research cigarettes.
2. The participant has reduced his/her cigarette
consumption by more than 50% compared to
baseline cigarettes per day. This does not include
situations such as illness.
Participants who are removed prior to randomization
(during Baseline Phases I and II) are replaced until a
total of 280 participants have been randomized.
Participants are monitored and may be withdrawn if
any of the following occurs:
1. Expired breath carbon monoxide (CO) increases
from baseline according to the following:
(a)CO level is greater than 50 ppm if CO at baseline
is <20 ppm.
(b)CO level is greater than 60 ppm if CO at baseline
is 20–34 ppm.
(c)CO level is greater than 70 ppm if CO at baseline
is 35–49 ppm.
(d)CO level is greater than 80 ppm if CO at baseline
is 50–60 ppm.
(e)CO level is greater than 90 ppm if CO at baseline
is 61–70 ppm.
2. Cigarettes per day increases by more than 100%
from average cigarettes per day at baseline
3. Increase in systolic blood pressure above 160 mmHg
4. Increase in substance abuse
5. Any hospitalization or debilitation in which
participation in the study could be detrimental to
the recovery process
6. Any missed visits where research cigarettes are given
7. Any situation where the participant is not able to
smoke the research cigarettes for a period of more
than 2 weeks
8. Participant behavior demonstrates an inability to
continue with the study
Participant withdrawal will occur at any point during
the study if the participant becomes pregnant, the par-
ticipant suffers from a serious medical condition (e.g.,
heart attack, stroke, blood clots), the participant decides
to withdraw, or for any other condition or situation that
would, in the investigator’s opinion, make it unlikely that
the participant could comply with the study protocol.
Recruitment process
Participants are recruited throughout the Hershey, PA and
Washington, DC areas by using traditional recruitment
methods (i.e., mailed and posted flyers, printed and radio
advertisements, community outreach events) in addition
to Internet and social media platforms (Craigslist, Face-
book) and word of mouth. They are screened for eligibility
over the phone and invited to the study centers where
they are further assessed for eligibility.
Procedures
The study flow diagram is given in Fig. 1. See Additional
file 1 for the Standard Protocol Items: Recommendations
for Interventional Trials (SPIRIT) checklist. Participants
complete biomeasures, questionnaires, and procedures
as outlined in Fig. 2 (the SPIRIT diagram). The Penn
State Tobacco Center of Regulatory Science (TCORS)
Biomarker Core will perform the analysis on all bio-
logical samples (blood, urine, saliva). Study visit proce-
dures are described in the following subsections.
Baseline Phase I: 1 week
During Visit 1, final eligibility determination and in-
formed consent are obtained from the participant by
trained study staff, and the usual discussion of proce-
dures, risks, side effects, confidentiality, voluntary par-
ticipation, and right to refuse participation without
prejudice is explained to the participant. Participants
must be capable of understanding the nature of this
study and its potential risks, discomforts, and benefits
before signing the consent form. After consent is ob-
tained, the study staff screens for drug abuse, obtains
medical and concomitant medication histories, and mea-
sures vital signs, with eligibility determination based on
the inclusion/exclusion criteria listed in Table 1. For
women of childbearing age, a urine sample is collected
for a pregnancy test.
Once a participant is determined eligible, further bio-
measures are obtained (i.e., exhaled CO). Participants
are asked to complete Visit 1 questionnaires (Fig. 2) on a
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computer, and the study staff reviews the study guide-
lines and provides participants with instructions on how
to keep track of the number of usual brand cigarettes
smoked each day by using a cigarette log (Fig 3). A ran-
domly selected subset of 200 participants is asked to
complete either a saliva sample collection (50 at each
study site) or a smoking topography protocol (50 at each
study site). If a participant is chosen to complete the sal-
iva sample collection, he/she is provided with a sample
kit that includes four saliva collection tubes and a sam-
ple log. On the day before the next study visit, partici-
pants place a cotton swab underneath their tongue for
2 minutes to obtain a saliva sample and will repeat this
four times throughout the day. Each time a sample is
taken, the time is recorded by the participant on the
sample log, along with additional questions about time
since last cigarette, stress events, exercise level, and alco-
hol consumed on the collection day. Participants are
asked to not eat or drink (especially caffeine or acidic
drinks) or brush their teeth 30 minutes before taking a
sample. Participants return the saliva kit at their visit the
next day. During the visit, participants watch an instruc-
tional video [55] on how to collect and store the saliva
samples. Participants who are chosen to complete the
smoking topography protocol are provided with a hand-
held, portable smoking topography device called the
Smoking Puff Analyzer-Mobile (SODIM SAS, Fleury-les-
Aubrais, France). The device mechanically records mea-
sures of smoking behavior (e.g., number of puffs, puff
flow, puff duration, inter-puff interval, and puff volume).
The participant smokes through a mouthpiece con-
nected by a tube to pressure transducers on the device.
Participants are shown an instructional video [55] on
how to operate and charge the device. For the next
2 days after the visit, they smoke their cigarettes with
the device and return it at the next visit.
During Visit 2, participants are asked to submit their
cigarette log from the prior week and to complete ques-
tionnaires. Biomeasures similar to Visit 1 are obtained,
except for height, waist, and hip measurements (Fig. 2).
Blood (~10 ml) and urine samples are collected for ana-
lysis at this visit and future visits (except Visit 11). All
Fig. 2 SPIRIT diagram
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participants are given a 2- week supply of SPECTRUM
research cigarettes containing a normal amount of nico-
tine (~11.6 mg) matching the flavor (regular or menthol)
of their usual brand of cigarettes. The supply of research
cigarettes given to the participant at each visit is equal
to their reported CPD*number of days until the next
visit (for Visit 2, this is 14 days), which is then multiplied
by 150% to ensure an adequate supply is distributed
until their next visit. Participants are asked to refrain
from using other smoked or nicotine-containing prod-
ucts for the remainder of the study and to return all
opened, unopened, and empty cigarette packs to the
study center at each visit. Participants randomized to
provide saliva return their samples to the study cen-
ter, where they are given another sample kit to
complete the day before the next study visit. Partici-
pants randomized to smoking topography return the
device, and their smoking files are downloaded. The
device is cleaned and redistributed for use on the
next 2 days after the study visit.
Baseline Phase II: 2 weeks
During this phase, participants complete a phone call
interview (lasting about 15 minutes) that consists of
questionnaires on their cigarette log (including any use
of other smoked or nicotine-containing products),
cigarette liking, smoking urges, and withdrawal symp-
toms, as outlined in Fig. 2. Visit 3 is similar to Visit 2
and includes the same biological measures, completion
of questionnaires, and collection of previous cigarette
logs and cigarette packs (Fig. 2). At Visit 3, if partici-
pants agree to continue in the study and did not meet
any of the early withdrawal criteria, they are randomized
to either (1) smoke the same UNC research cigarettes
(~11.6 mg) for 18 weeks or (2) switch to progressively
RNC research cigarettes over 18 weeks (Table 2). Partici-
pants receive a 3-week supply of research cigarettes to
last until their next visit along with cigarette logs to fill
out showing daily cigarette consumption. Again, ran-
domized participants return saliva samples and the
smoking topography device, and a new sample kit and a
clean device are given.
Randomization Phase: 18 weeks
During the Randomization Phase, participants return to
the study center every 3 weeks for a total of six visits
(Visits 4–9) to complete biomeasures and questionnaires
as outlined in Fig. 2. Prior visit cigarette packs are col-
lected. New research cigarettes equal to a 3-week supply
corresponding to their treatment group are given at each
visit. As with all study contacts, previous cigarette logs
and information on use of other smoked or nicotine-
containing products are collected. Any changes in health
or medications are documented at each visit. Partici-
pants taking saliva samples and using the smoking top-
ography device continue with the protocol until Visit 8.
Participants are contacted for phone call interviews one
week after Visits 4–8 to complete questionnaires as out-
lined in Fig. 2.
At Visit 9, the last visit of the Randomization Phase,
participants are given the option as to how they would
like to proceed with the next phase of the study. The
three options are:
1. Return to their usual brand of cigarettes for
12 weeks (at their own cost)
2. Continue to receive research cigarettes for 12 weeks
(provided at no cost)
3. Quit smoking with brief counseling from the study
team and the option to use oral nicotine
replacement therapy (NRT [2 mg gum or lozenges])
for 11 weeks (provided at no cost)
All participants receive a copy of the US Surgeon Gen-
eral Report, How Tobacco Smoke Causes Disease: What
Fig. 3 Participants are instructed to keep their daily cigarette log
attached to their cigarette pack by folding the top of the log at the
line and tucking the flap into the pack
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It Means to You [56] and local resources to help
smokers quit. If participants choose to return to their
usual brand of cigarettes, they are no longer given re-
search cigarettes and are removed from the CMS, given
additional cigarette logs, and are instructed to bring all
logs back to the next study visit. If participants choose
to continue on research cigarettes, they are given a 4-
week supply of research cigarettes equivalent in nicotine
content to the cigarettes they were given at the last visit,
additional cigarette logs, and instructed to bring all logs
and research cigarette packs back to the next study visit.
If participants choose to quit smoking, they are given up
to a 6-day supply of research cigarettes equivalent in
nicotine content to the cigarettes they were given at the
last visit and additional cigarette logs. These cigarettes
are intended to last until their target quit date. Partici-
pants who choose to quit set a quit date approximately
1 week later and return to the study center after an ap-
proximately 24-hour period of abstinence so that the se-
verity of their withdrawal can be assessed prior to
dosing NRT. Additional information for the quit option
is outlined below.
Treatment Choice Phase: 12 weeks
Regardless of the participant’s choice, all participants at-
tend Visits 10 and 11 during the Treatment Choice
Phase. During these visits, participants complete ques-
tionnaires and biomeasures as outlined in Fig. 2. Any
changes in health or medications are documented. At
Visit 10, participants who return to their usual brand
continue on their own brand. Participants continuing to
receive research cigarettes are given an 8-week supply of
research cigarettes equivalent in nicotine content to the
cigarettes they were given at the last visit. Participants
still smoking return previous cigarette logs, and new logs
are given. Participants making a quit attempt are offered
a refill of NRT (three boxes of gum or lozenges) if
needed and counseling on their quit attempt. At the
final visit (Visit 11), all participants continuing to smoke
return their cigarette logs and participants on research
cigarettes return all packs. No more research cigarettes
or NRT is given.
Additional contacts for the quit option
Participants who choose to quit receive additional
study contacts during the Treatment Choice Phase to
facilitate a cessation intervention based on best prac-
tices developed for tobacco use. This includes cost-
free behavioral interventions and FDA-approved
medications for smoking cessation. Participants must
be willing to set a quit date and are offered a flexible
smoking cessation treatment. They have the option
to receive up to 11 weeks of FDA-recommended
doses of oral NRT (2 mg gum or lozenges) at no
cost and cognitive behavioral-based smoking cessa-
tion counseling provided by study staff (in person or
over the phone). In addition to the two regular study
visits (Visit 10 [week 26] and Visit 11 [week 34]),
there are two additional in-person counseling ses-
sions (weeks 23 and 30), four phone counseling ses-
sions (weeks 23, 24, 28, and 32), and five participant
self-guided sessions. Participants receive 20 minutes
(or less) at each session of standard individual cogni-
tive behavioral therapy based on the Freedom from
Smoking curriculum [57] from the American Lung
Association. Standardized supplemental materials on
cessation are provided.
Compensation
Participants receive a $20 gift card at each study visit to
cover parking, meals, or travel to the 11 study visits
($220). Participants receive $20 for the first and last
study visits. Participants receive $60 for completing each
of the remaining 9 study visits ($580). Participants re-
ceive $10 for each of the seven phone surveys they
complete ($70). If participants complete all study visits
and return used and unused cigarette packs and study
equipment (e.g., the smoking topography device) they
receive a $130 study compliance payment at the last
visit. The total compensation is $1000.
Participants who used the smoking topography device
throughout the study receive an additional one-time
check payment of $60 for completing this extra protocol
at the last study visit. Participants who provided saliva
samples throughout the study receive an additional one-
time check payment of $35 for completing this protocol
at the last study visit. If the participant does not
complete the protocol, they do not receive payment.
Sample size
It is estimated that we will recruit 400 participants (200
white and 200 black smokers), allowing for a 30% post
randomization withdraw rate, to allow for 280 partici-
pants completing the entire protocol. Sample size calcu-
lations are based on a secondary aim, total plasma
cotinine concentration (measured as nanograms per
milliliter). A total sample size of 280 participants (70 per
group* 2 treatment groups* 2 races) will enable us to de-
tect a mean cotinine difference of 68 ng/ml as observed
in the Benowitz et al. [36] trial with at least 90% power.
Data management and monitoring
All study data are collected and managed across sites
using Research Electronic Data Capture (REDCap) [58]
tools hosted at the Penn State Milton S. Hershey Med-
ical Center and College of Medicine. REDCap is a se-
cure, web-based application designed to support data
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capture for research studies. Access to the REDCap
database requires double authentication (two unique
usernames and passwords), and a user matrix is used to
ensure that only appropriate data are accessed based on
the individual’s role in the project. Any paper records
generated during the trial will be stored in locked file
cabinets in areas with limited access. Trial data will
undergo internal auditing by an independent data man-
agement team at Penn State University. The Data Moni-
tors will review source documentation to determine
whether the data reported in the web-based system are
complete and accurate and verify that standard operat-
ing procedures and policies are followed during study
implementation.
Adverse event reporting and review is ongoing
throughout the trial. The Safety Monitor (Rebecca Bas-
com) oversees the safety of the participants in the trial
and assesses the causality of all adverse events. Adverse
events will be reported to the applicable institutional re-
view boards (IRBs) in accordance with IRB policies and
procedures. All serious adverse events are reported
within 5 days to the FDA’s Center for Tobacco Products
Safety Reporting Portal. The Monitor receives summary
data safety monitoring reports on recruitment, retention,
adverse events, cigarettes per day, and CO, and produces
bi-annual reports and recommendations on the continu-
ation of the research to the principal investigators.
Statistical analysis
Basic baseline statistics including means (standard devia-
tions) and frequency distributions (percentages) will be
reported for demographic characteristics, smoking charac-
teristics, nicotine dependence, and nicotine and toxicant
exposure. Characteristics will be reported by the two
groups under investigation to identify treatment group im-
balances. Numerical baseline characteristics will be com-
pared between the two groups using two-sample t tests or
non-parametric Wilcoxon rank sum tests when appropri-
ate. Suitably transformed variables will be used when
necessary. Categorical variables will be compared using
chi-square tests or Fisher’s exact tests. The analysis of all
endpoints will adhere to the intention-to-treat principle,
where all randomized participants will be included in the
analysis regardless of compliance or study completion.
The frequency of smokers who drop out and the degree
of non-compliance will be summarized for each treatment
group. The levels of within-subject cotinine normalized for
the number of cigarettes smoked will be used to measure
the degree of compliance using the RNC cigarettes ([plasma
cotinine/CPD (end of randomization)]/[plasma cotinine/
CPD (baseline)]) as first described by Benowitz et al. (2015)
[40]. Self-report measures of use of other nicotine-
containing products including usual brand cigarettes will
also be assessed. The two-sample t test or nonparametric
Wilcoxon rank sum test will be used to compare the nico-
tine metabolite measurements between groups with and
without drop-out/relapse. Fisher’s exact test will be used to
compare the drop-out/relapse rate between the two groups.
A multi-variable logistic regression model will be built to
examine the significance of the preceding factors on the
drop-out/relapse rate. The magnitude of the effectiveness
of each factor will be quantified by the estimated odds ratio
with its 95% confidence interval. In addition, the sensitivity,
specificity, and positive and negative predictive values in
using these predictors to classify the outcome (drop-out
versus non drop-out) will be estimated. The interaction be-
tween the predictors will also be explored in the analysis.
Each of the secondary outcome variables of interest will
be analyzed within and across time periods. Results will be
summarized by tables and figures (such as boxplots). Pro-
file plots will be generated to show the trajectory of vari-
ables across different time periods. The major analytical
tool for addressing the specific aims of this study is linear
mixed models with repeated measures. For each bio-
marker and other numerical outcome measures of inter-
est, a linear mixed repeated measures model will be fit to
evaluate the main effects of time, group, and time-by-
group interaction, treating baseline scores for outcomes as
covariates. Known confounders will be included in the lin-
ear models, and other covariates will be included if their
individual bivariate associations with both the group vari-
able and outcome are significant at a 10% level. A sub-
group analysis will be performed by race. We will also test
for a number of potential effect modifiers by pooling the
trial data of white smokers and black smokers.
To determine modification effects, such as menthol,
the menthol-by-group interaction in the multi-variable
linear mixed model will be examined. The three-way
interaction of menthol-by-group-by-time will be ex-
plored but will be removed from the model if not signifi-
cant. If the menthol-by-group interaction is found
significant, then mean-profile plots will be used to show
the interaction in detail.
Stress measures will be examined by both salivary bio-
markers and psychological questionnaires. The mean
cortisol values (average of four measurements) over dif-
ferent time points will be converted to area under the
curve (AUC), which is an aggregate index based on re-
peated measures over time of day. Two different calcula-
tions will be made; one is AUCg (ground), which
measures total area under the curve, and the other is
AUCi (increase), which measures change beyond base-
line over time. We will use t tests to compare salivary
cortisol and alpha amylase measures between the two
study groups at each time point.
Analyses will be conducted by the Penn State TCORS
Biostatistics Core using statistical software SAS version
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9.4 or higher (SAS Institute, Cary, NC, USA) and the R
programming language version 3.3.2 or higher (R Founda-
tion). The smoking topography data will be preprocessed
(before statistical analysis) using the Python programming
language version 2.7 (Python Software Foundation). All
tests will be two-sided, and the statistical significance level
to be used is 0.05. Results pertaining to study outcomes
will be reported on ClinicalTrials.gov.
Discussion
The purpose of the Penn State TCORS is to provide
evidence-based policy research on tobacco regulatory ac-
tions. There are various levels of nicotine content in re-
duced nicotine cigarettes, and empirical data are needed
to determine the optimal strategies for reducing
cigarette exposure, including the dosing, time and dur-
ation of doses, individual variation, and potential harm
from nicotine reduction. This study focuses on progres-
sively switching smokers from a high nicotine commer-
cial cigarette to a very low nicotine content cigarette in a
tapered fashion over time. Progressively reducing nico-
tine might facilitate the ability to switch to low nicotine
cigarettes while minimizing any potential harm. One of
the major goals of the Penn State TCORS is to evaluate
RNC cigarettes in vulnerable populations who are af-
fected the hardest by the detrimental health effects of
smoking and the degree of nicotine dependence. To-
bacco use and dependence are highly associated with
low SES, homelessness, imprisonment, and mental
health disorders [7, 59–61]. Consequently, research on a
potential national policy that includes these populations
should establish feasibility and safety. A reduced nicotine
strategy may positively impact low SES populations who
disproportionately consume tobacco and experience its
deleterious health effects. Clinical trial data of the bene-
fits and harms of RNC cigarettes are used by the FDA in
the evaluation process of lowering nicotine in cigarettes.
Trial status
The trial started recruiting participants in August 2015
and is currently enrolling participants. Trial findings are
likely to be available in early 2019.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 121 kb)
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